Early ctDNA reduction is associated with better overall survival in the Ph 3 trial of tebentafusp in previously untreated metastatic uveal melanoma

被引：0
|
作者：
Sullivan, Ryan
Collins, Laura
Rodrigues, Manuel
Nathan, Paul
Hassel, Jessica C.
Dummer, Reinhard
Kirkwood, John
Rutkowski, Piotr
Baurain, Jean-Francois
Butler, Marcus O.
Schlaak, Max
Ochsenreither, Sebastian
Abdullah, Shaad E.
Holland, Chris
Ranade, Koustubh
Shoushtari, Alexander N.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1035
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma.
    Piperno-Neumann, Sophie
    Hassel, Jessica C.
    Rutkowski, Piotr
    Baurain, Jean-Francois
    Butler, Marcus O.
    Schlaak, Max
    Sullivan, Ryan J.
    Ochsenreither, Sebastian
    Dummer, Reinhard
    Kirkwood, John M.
    Joshua, Anthony M.
    Sacco, Joseph J.
    Shoushtari, Alexander N.
    Orloff, Marlana
    Carvajal, Richard D.
    Hamid, Omid
    Abdullah, Shaad E.
    Holland, Chris
    Goodall, Howard
    Nathan, Paul
    CANCER RESEARCH, 2021, 81 (13)
  • [22] Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
    Piulats, J. M.
    Watkins, C.
    Costa-Garcia, M.
    del Carpio, L.
    Piperno-Neumann, S.
    Rutkowski, P.
    Hassel, J. C.
    Espinosa, E.
    de la Cruz-Merino, L.
    Ochsenreither, S.
    Shoushtari, A. N.
    Orloff, M.
    Salama, A. K. S.
    Goodall, H. M.
    Baurain, J. -F.
    Nathan, P.
    ANNALS OF ONCOLOGY, 2024, 35 (03) : 317 - 326
  • [23] PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp
    Rodrigues, Manuel
    Saint-Ghislain, Mathilde
    Ramtohul, Toulsie
    de Koning, Leanne
    Bouchez, Clementine
    Lafite, Elsa
    Ajgal, Zahra Castel
    Marret, Gregoire
    Sanchez, Raphael
    Mariani, Pascale
    Nespoulous, Sandra
    Gillon, Veronique
    Servois, Vincent
    Piperno-Neumann, Sophie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a Phase 3 randomized trial comparing tebe vs. investigator's choice (IC) in first line metastatic uveal melanoma
    Hassel, Jessica C.
    Rutkowski, Piotr
    Baurain, Jean-Francois
    Butler, Marcus O.
    Schlaak, Max
    Sullivan, Ryan J.
    Ochsenreither, Sebastian
    Dummer, Reinhard
    Kirkwood, John M.
    Joshua, Anthony M.
    Sacco, Joseph J.
    Shoushtari, Alexander N.
    Orloff, Marlana
    Carvajal, Richard D.
    Hamid, Omid
    Abdullah, Shaad E.
    Holland, Chris
    Goodall, Howard
    Nathan, Paul
    Piperno-Neumann, Sophie
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (SUPPL 1)
  • [25] Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).
    Olson, Daniel
    Bao, Riyue
    Allred, Jacob B.
    Strand, Carrie
    Zha, Yuanyuan
    Carll, Timothy C.
    Labadie, Brian
    Bastos, Bruno R.
    Butler, Marcus O.
    Munster, Pamela N.
    Schwartz, Gary K.
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
    Orloff, M.
    Watkins, C.
    Carvajal, R. D.
    Shoushtari, A. N.
    Sacco, J. J.
    Schlaak, M.
    Gama, J.
    Butler, M. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S678 - S678
  • [27] Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma.
    Hassel, Jessica Cecile
    Rutkowski, Piotr
    Baurain, Jean-Francois
    Butler, Marcus O.
    Schlaak, Max
    Sullivan, Ryan
    Ochsenreither, Sebastian
    Dummer, Reinhard
    Kirkwood, John M.
    Joshua, Anthony M.
    Sacco, Joseph J.
    Shoushtari, Alexander Noor
    Orloff, Marlana
    Carvajal, Richard D.
    Hamid, Omid
    Abdullah, Shaad Essa
    Holland, Chris
    Goodall, Howard
    Nathan, Paul
    Piperno-Neumann, Sophie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years
    Tawbi, Hussein A.
    Hodi, F. Stephen
    Lipson, Evan J.
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Matamala, Luis
    Gutierrez, Erika Castillo
    Rutkowski, Piotr
    Gogas, Helen
    Lao, Christopher D.
    Menezes, Juliana
    Dalle, Stephane
    Arance, Ana Maria
    Grob, Jean-Jacques
    Ratto, Barbara
    Rodriguez, Saima
    Mazzei, Antonella
    Dolfi, Sonia
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] EXPLORING ENDPOINT CORRELATION BETWEEN PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PREVIOUSLY UNTREATED METASTATIC MELANOMA USING PSEUDO INDIVIDUAL PATIENT DATA (IPD)
    Kanters, S.
    Kurt, M.
    Moshyk, A.
    Leung, L.
    VALUE IN HEALTH, 2022, 25 (12) : S20 - S20
  • [30] SF3B1 mutation predicts improved overall survival in metastatic uveal melanoma patients: Molecular and clinical correlates
    del Carpio Huerta, L. P.
    Varela, M.
    Goma, M.
    Purqueras, E.
    Lorenzo, D.
    Gutierrez, C.
    Slocker, A.
    Caminal, J.
    Piulats Rodriguez, J. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S679 - S680
12345